Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare To Use Evidence Development For Off-Label Drug Use? CMS Guidance Unclear

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS’ guidance on its “coverage with evidence development” policy for Medicare Part B does not elaborate on the scope of its application to off label drug use, only stating the agency could apply CED to drugs that have received FDA approval for at least one indication.

You may also be interested in...

Medicare Part B, Breakthrough Drugs Get Reimbursement Boost In Senate COVID-19 Bill

Legislation allows sponsors to request HCPCS code even before US FDA approval, but would extend the sequester until 2030 to pay for the temporary increase in payments for Part B drugs.

Paying For Placebo Is ‘Biggest Change’ In Medicare CED Policy, Official Says

The director of Medicare’s coverage group sees the ability to pay physicians for providing a placebo in clinical trials required under a ‘coverage with evidence development’ determination as a major improvement in its recent guidance for CED.

Medicare CED Not A Good Fit With Groundbreaking Products, Drug Firms Argue

In comments on CMS’ recent draft guidance on Medicare coverage with evidence development, Onyx Pharmaceuticals recommends that cutting edge therapies with postmarketing commitments like its cancer drug Kyprolis should be exempted, and Amyvid marketer Lilly says CED is not appropriate for radiopharmaceuticals.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts